clinical trial · NCT06548347
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd.·phase3·not yet recruiting·n = 606
Peripheral T Cell LymphomaLinperlisib
brief summary
This is a Phase II/III, international multiple center study to evaluate the efficacy, safety, and PK of Linperlisib plus CHOP and CHOP in adult patients with Newly Diagnosed Peripheral T Cell Lymphoma.
started
Sep 10, 2024
primary completion
Dec 31, 2024
completion
Sep 30, 2029
last updated
Aug 12, 2024
official title
A International Multicenter, Randomized, Double-Blind, Controlled Phase II/III Study to Evaluate the Efficacy and Safety of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol